Related Experiment Video
Updated: Jan 22, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Placenta-specific 8 is a potential novel target for osimertinib resistance in non-small cell lung cancer
Xiaoyun Fei1, Gang Wang2, Hui Shen1
1Department of Respiratory Medicine, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China.
Abstract:
Currently, osimertinib (AZD9291) is the only third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor approved by the Food and Drug Administration for the treatment of non-small cell lung cancer (NSCLC) with EGFR T790M mutations. However, acquired resistance is an inevitable clinical challenge. Although placenta-specific 8 (PLAC8) has been proven to serve an important role in tumor progression and resistance, its effect in AZD9291 resistance in NSCLC remains largely unknown. The aim of the present study was to investigate the functional role of PLAC8 in AZD9291 resistance in NSCLC. The results revealed that the level of PLAC8 was significantly upregulated in AZD9291-resistant cells compared with that in parent cells. Overexpression of PLAC8 in parent cells markedly decreased drug sensitivity, and enhanced cell proliferation, colony formation and migration. Furthermore, the levels of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) were observed to be upregulated in resistant cells and PLAC8-overexpressing parent cells, suggesting that ALDH1A1 may be involved in the association between the overexpression of PLAC8 and AZD9291 resistance in NSCLC. Overall, PLAC8 overexpression promoted NSCLC resistance to AZD9291, and PLAC8 may be a potential target for the reversal of AZD9291 resistance.
Insights
Placenta-specific 8 (PLAC8) overexpression promotes resistance to osimertinib (AZD9291) in non-small cell lung cancer (NSCLC). Targeting PLAC8 may help overcome this drug resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osimertinib (AZD9291), a third-generation EGFR-TKI, treats NSCLC with EGFR T790M mutations.
- Acquired resistance to osimertinib is a significant clinical challenge.
- Placenta-specific 8 (PLAC8) is implicated in tumor progression and resistance, but its role in osimertinib resistance is unclear.
Purpose of the Study:
- To investigate the functional role of PLAC8 in osimertinib (AZD9291) resistance in non-small cell lung cancer (NSCLC).
Main Methods:
- Comparison of PLAC8 levels in AZD9291-resistant and parent NSCLC cells.
- Overexpression of PLAC8 in parent NSCLC cells to assess drug sensitivity, proliferation, colony formation, and migration.
- Analysis of aldehyde dehydrogenase 1 family member A1 (ALDH1A1) levels in resistant and PLAC8-overexpressing cells.
Main Results:
- PLAC8 levels were significantly upregulated in AZD9291-resistant NSCLC cells.
- Overexpression of PLAC8 in parent cells reduced sensitivity to AZD9291 and enhanced proliferation, colony formation, and migration.
- ALDH1A1 levels were also upregulated in resistant and PLAC8-overexpressing cells, suggesting its involvement.
Conclusions:
- PLAC8 overexpression contributes to NSCLC resistance to AZD9291.
- PLAC8 is a potential therapeutic target for overcoming AZD9291 resistance in NSCLC.
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
Cell Specific Gene Expression
Lung Capacity
Resistivity

